US008586045B2

(12) **United States Patent**
Zeller et al.

(10) **Patent No.: US 8,586,045 B2**
(45) **Date of Patent: Nov. 19, 2013**

(54) **METHODS OF USING ANTI-CGRP ANTAGONIST ANTIBODIES**

(75) Inventors: **Joerg Zeller**, Ann Arbor, MI (US); **Kristian T. Poulsen**, San Francisco, CA (US); **Yasmina Noubia Abdiche**, Mountain View, CA (US); **Jaume Pons**, San Bruno, CA (US); **Sierra Lee Jones Collier**, Menlo Park, CA (US); **Arnon Rosenthal**, Woodside, CA (US)

(73) Assignee: **Labrys Biologics, Inc.**, San Mateo, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 12 days.

(21) Appl. No.: **13/179,846**

(22) Filed: **Jul. 11, 2011**

(65) **Prior Publication Data**

US 2012/0009192 A1 Jan. 12, 2012

Related U.S. Application Data

(62) Division of application No. 12/093,638, filed as application No. PCT/IB2006/003181 on Nov. 2, 2006, now Pat. No. 8,007,794.

(60) Provisional application No. 60/736,623, filed on Nov. 14, 2005.

(51) **Int. Cl.**

A61K 39/395	(2006.01)
C12P 21/08	(2006.01)
C07K 16/00	(2006.01)

(52) **U.S. Cl.**

USPC **424/145.1**; 424/130.1; 424/133.1; 424/141.1; 530/387.1; 530/387.3; 530/388.1; 530/388.24

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,116,964	A	5/1992	Capon et al.	
7,479,488	B2	1/2009	Mueller et al.	
8,007,794	B2	8/2011	Zeller et al.	
8,293,239	B2	10/2012	Poulsen et al.	
8,298,536	B2	10/2012	Poulsen et al.	
2004/0110170	A1	6/2004	Pisegna et al.	
2005/0234054	A1	10/2005	Mueller et al.	514/229.8
2006/0183700	A1	8/2006	Vater et al.	
2012/0225075	A1	9/2012	Pios et al.	

FOREIGN PATENT DOCUMENTS

EP	0 212 432	A2	3/1987	
EP	1031350	A1	8/2000	
JP	08-268874	A	10/1996	
WO	WO 03/093472	A2	11/2003	
WO	WO 2004003019		1/2004	C07K 16/00
WO	WO 03/093472	A3	3/2004	
WO	WO 2004/003019	A3	9/2004	
WO	WO 2005/100360	A1	10/2005	
WO	WO 2006/077212	A1	7/2006	
WO	WO 2007/025212	A2	3/2007	
WO	WO 2007/054809	A2	5/2007	
WO	WO 2007/061676	A2	5/2007	
WO	WO 2007/076336	A1	7/2007	
WO	WO 2007/054809	A3	8/2007	
WO	WO 2007/025212	A3	12/2007	
WO	WO 2007/061676	A3	12/2007	
WO	WO 2008/011190	A1	1/2008	

OTHER PUBLICATIONS

U.S. Appl. No. 13/621,981, filed Sep. 18, 2012, Poulsen et al.

U.S. Appl. No. 13/623,206, filed Sep. 20, 2012, Poulsen et al.

Adwanikar, et al. Spinal CGRP1 receptors contribute to supraspinally organized pain behavior and pain-related sensitization of amygdala neurons. Pain. Nov. 2007;132(1-2):53-66. Epub Mar. 1, 2007.

Ambalavanar, et al. Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist. Pain. Jan. 2006;120(1-2):53-68. Epub Dec. 13, 2005.

Aziz. Visceral hypersensitivity: fact or fiction. Gastroenterology. Aug. 2006;131(2):661-4.

Bennett, et al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chronic central pain. Pain. May 2000;86(1-2):163-75.

Delafoy, et al. Interactive involvement of brain derived neurotrophic factor, nerve growth factor, and calcitonin gene related peptide in colonic hypersensitivity in the rat. Gut. Jul. 2006;55(7):940-5. Epub Jan. 9, 2006.

Elshourbagy, et al. Molecular cloning and characterization of the porcine calcitonin gene-related peptide receptor. Endocrinology. Apr. 1998;139(4):1678-83.

European search report dated May 8, 2012 for EP Application No. 11166787.9.

International seach report and written opinion dated Jul. 29, 2009 for PCT/IB2009/050852.

International seach report and written opinion dated Jul. 31, 2009 for PCT/IB2009/050849.

International seach report and written opinion dated Nov. 11, 2010 for PCT/IB2010/053787.

Julia, et al. Tachykininergic mediation of viscerosensitive responses to acute inflammation in rats: role of CGRP. Am J Physiol. Jan. 1997;272(1 Pt 1):G141-6.

Kawamura, et al. Antinociceptive effect of intrathecally administered antiserum against calcitonin gene-related peptide on thermal and mechanical noxious stimuli in experimental hyperalgesic rats. Brain Res. Sep. 11, 1989;497(1):199-203.

Kuraishi, et al. Antinociception induced in rats by intrathecal administration of antiserum against calcitonin gene-related peptide. Neurosci Lett. Oct. 17, 1988;92(3):325-9.

(Continued)

Primary Examiner — Christine J Saoud

Assistant Examiner — Jon M Lockard

(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich & Rosati

(57) **ABSTRACT**

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

31 Claims, 16 Drawing Sheets